

Expecto Health Science appoints Dr. Samir Sadekar as Vice President, Clinical Operations

23 July 2025 | News

Strategic leadership hire strengthens Expecto's APAC clinical trial capabilities and supports its mission for globally trusted, patient-centric research delivery



Expecto Health Science, a fast-growing Contract Research Organization (CRO) headquartered in Singapore, is pleased to announce the appointment of **Dr. Samir Sadekar** as **Vice President, Clinical Operations**. This strategic hire supports Expecto's ambitious growth plans to become a leading APAC-focused CRO known for scientific excellence, regional expertise, and globally trusted clinical trial delivery.

With over two decades of experience in clinical research and drug development, Dr. Sadekar brings deep expertise in clinical operations, regulatory strategy, and cross-functional team leadership across international markets. He has held senior roles at multinational pharmaceutical companies and global CROs, leading successful clinical programs across therapeutic areas such as oncology, immunology, and rare diseases.

Dr. Sadekar is widely recognised in the industry for his visionary leadership, operational rigour, and commitment to advancing patient centric research. His addition to the leadership team at Expecto will further strengthen the company's capability to deliver high-quality, efficient, and compliant clinical trials across Asia-Pacific and beyond.

"We are thrilled to welcome Dr. Samir Sadekar to Expecto," said Dr. Pramod Kashid, CEO of Expecto Health

Science. **“His wealth of experience and leadership style aligns perfectly with our mission to transform clinical research delivery in the APAC region. This is a pivotal step in scaling our operational capabilities and serving our global clients with excellence.”**

As Vice President of Clinical Operations, Dr. Sadekar will oversee clinical delivery teams, drive operational strategy, and play a key role in expanding Expecto's presence across emerging APAC markets. His leadership will support Expecto's ongoing efforts to uphold scientific integrity, regulatory compliance, and promote patient diversity in clinical development.